Belen Carrillo-Rivas

Belen Carrillo-Rivas, D.Phil. has extensive experience in regulatory affairs and quality in the pharmaceutical industry. Belen is currently serving as the Senior Vice President and Head of Regulatory Affairs and Quality at Structure Therapeutics since October 2023. Prior to this, they held the position of Senior Vice President and Head of Regulatory Affairs at the same company.

Before joining Structure Therapeutics, Carrillo-Rivas worked at Imvax, Inc. as the Senior Vice President and Head of Regulatory Affairs from June 2022 to May 2023. In this role, they pioneered the regulatory path for Imvax's GoldspireTM platform and developed the regulatory strategy for the company's portfolio.

Belen also served as the Vice President and Global Head of Regulatory Affairs at Saniona from March 2021 to May 2022. In this position, Carrillo-Rivas played a key role in developing and executing the company's global regulatory strategy and enhancing the likelihood of regulatory approval for Saniona's medicines.

Carrillo-Rivas has a strong background in regulatory affairs at Pfizer, where they held various leadership roles. From July 2018 to February 2021, they worked as the Head of Global Clinical Submissions Quality in the Global Regulatory Affairs division. Belen also served as the Lead for Global Clinical Submissions Quality and the Lead for Pfizer CURES, Worldwide Research and Development, and Pfizer Medical.

Prior to joining Pfizer, Carrillo-Rivas held positions at Resolvyx Pharmaceuticals, Inc., Peptimmune, Daichii Sankyo, Enanta Pharmaceuticals, and Harvard Medical School, where they gained valuable experience in pharmacology and research.

Overall, Belen Carrillo-Rivas, D.Phil. possesses a strong background in regulatory affairs and quality management in the pharmaceutical industry, with a focus on pioneering regulatory strategies and accelerating development and approval of medicinal products.

Belen Carrillo-Rivas obtained a D.Phil. in Human/Medical Genetics from the University of Oxford. Following that, they pursued a Postdoctoral Research Fellowship in Cellular Immunology at Harvard Medical School from 1997 to 2001.